Cargando…

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling

OBJECTIVE: To determine whether unsupervised principal component analysis (PCA) of comprehensive clinico-radiologic data can identify phenotypic subgroups within antibody-negative patients with overlapping features of multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSDs), and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeo, Tianrong, Probert, Fay, Jurynczyk, Maciej, Sealey, Megan, Cavey, Ana, Claridge, Timothy D.W., Woodhall, Mark, Waters, Patrick, Leite, Maria Isabel, Anthony, Daniel C., Palace, Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865851/ https://www.ncbi.nlm.nih.gov/pubmed/31659123 http://dx.doi.org/10.1212/NXI.0000000000000626

Ejemplares similares

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease
por: Jurynczyk, Maciej, et al.
Publicado: (2017)

Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO
por: Kitley, Joanna, et al.
Publicado: (2015)

Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis
por: Probert, Fay, et al.
Publicado: (2021)

A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application
por: Yeo, Tianrong, et al.
Publicado: (2020)

Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
por: Yeo, Tianrong, et al.
Publicado: (2022)

Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach
por: Yeo, Tianrong, et al.
Publicado: (2021)

Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands
por: Probert, Fay, et al.
Publicado: (2022)

Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands
por: Probert, Fay, et al.
Publicado: (2022)

Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis
por: Juryńczyk, Maciej, et al.
Publicado: (2021)

Double-negative neuromyelitis optica spectrum disorder
por: Wu, Yan, et al.
Publicado: (2023)

Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis
por: Messina, Silvia, et al.
Publicado: (2021)

Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
por: Larkin, James R., et al.
Publicado: (2022)

Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies
por: Yeo, Tianrong, et al.
Publicado: (2020)

Plasma Nuclear Magnetic Resonance Metabolomics Discriminates Between High and Low Endoscopic Activity and Predicts Progression in a Prospective Cohort of Patients With Ulcerative Colitis
por: Probert, Fay, et al.
Publicado: (2018)

Finding NMO
por: Daneman, Richard
Publicado: (2016)

The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis
por: Lennox, Belinda, et al.
Publicado: (2022)

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
por: Waters, Patrick, et al.
Publicado: (2015)

Therapy of NMO spectrum disorders
por: Biswas, Atanu, et al.
Publicado: (2015)

Frequency of MOG-IgG in cerebrospinal fluid versus serum
por: Pace, Samuel, et al.
Publicado: (2022)

Neurodegeneration in MS and NMO: The Eye and the Blood
por: Petzold, Axel, et al.
Publicado: (2011)

Neuromyelitis optica (NMO) and autoimmune thyroiditis
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015)

Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD
por: Zeka, Bleranda, et al.
Publicado: (2016)

Autoimmune thyroiditis associated with neuromyelitis optica (NMO)
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015)

Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease: CHANCE(NMO) Study
por: Hümmert, Martin W., et al.
Publicado: (2022)

Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica
por: Wilson, Robert, et al.
Publicado: (2018)

Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
por: Borisow, Nadja, et al.
Publicado: (2018)

Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO?
por: Kinoshita, Makoto, et al.
Publicado: (2012)

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
por: Weinshenker, Brian G., et al.
Publicado: (2006)

Wallenda-Nmo Axis Regulates Growth via Hippo Signaling
por: Wang, Xianping, et al.
Publicado: (2021)

Wernicke’s Encephalopathy Precipitated by Area Postrema Syndrome of NMO-SD
por: Anuradha, Mahto, et al.
Publicado: (2023)

Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO
por: Gelfand, Jeffrey M., et al.
Publicado: (2014)

Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
por: Vaknin-Dembinsky, Adi, et al.
Publicado: (2016)

3D-DIR for early differential diagnostic and prognostic evaluation of NMO
por: Wang, Yanbing, et al.
Publicado: (2016)

Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO
por: Higuchi, Osamu, et al.
Publicado: (2016)

Identification of geraldol as an inhibitor of aquaporin-4 binding by NMO-IgG
por: Wang, Jie, et al.
Publicado: (2020)

COVID-19 infection in NMO/SD patients: a French survey
por: Zeidan, Sinéad, et al.
Publicado: (2020)

An Atypical Presentation of Chronic Inflammatory Myelin Degeneration in Neuromyelitis Optica (NMO)
por: Allu, Sai Vishnu Vardhan, et al.
Publicado: (2023)

Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?
por: Fujihara, Kazuo, et al.
Publicado: (2014)

Unmasking and provoking severe disease activity in a patient with NMO spectrum disorder
por: Kornberg, Michael D., et al.
Publicado: (2015)

Vitamin D and Demyelinating Diseases: Neuromyelitis Optica (NMO) and Multiple Sclerosis (MS)
por: Rodney, Cady, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_395sd77t8a56nipvi06nc815pm